The DOI matches its Crossref record; 277 of the 277 references it cites were found in a registry or an index; 62 of the 203 sources its claims cite were checked for support.
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Open accessAbstract
AASLD practice guidance on diagnostic and therapeutic care of PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
61 No full text of the sources · 19 Partly supported · 18 No basis given · 15 Supported · 11 Not checked yet · 8 Sources not found · 6 Supported so far · 6 Own interpretation · 5 Couldn’t confirm · 4 Not supported · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“while the largest study found that only 8 of 1,476 patients with PBC later developed AIH.(120)”
What the sources say
- Disputedcites [120] 120. Gossard AA, Lindor KD. Development of autoimmune hepa- titis in primary biliary cirrhosis. Liver Int. 2007;27:1086-1090. 121 sourceExperimental — accuracy not yet measured
The Abstract and the ‘Frequency and Baseline Characteristics’ section report that 12 of 282 PBC patients developed AIH during follow-up, not 8 of 1,476. No page number is supplied for these passages in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
What the sources say
- Disputedcites [160] 160. Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, et al. A randomized trial of obeti- cholic acid monotherapy in patients with primary biliary chol- angitis. Hepatology. 2018;67:1890-1902. 161 sourceExperimental — accuracy not yet measured
The Trial Design section describes a phase 3 trial with placebo, 5–10-mg, and 10-mg groups, not a phase 2 study with a 50-mg group. The Secondary End Points section reports 12-month ALP reductions of 113, 130, and 14 U/L in those groups, respectively, rather than the claimed percentages. Page numbers were not available in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plaindirectn = 59- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A phase 2 randomized controlled trial evaluated 3 doses of OCA (10 mg, 25 mg, and 50 mg) against placebo for 3 months in a study including 165 patients.(159) A 21% to 25% reduction in ALP was achieved in the OCA groups compared with 3% reduction in the placebo group.”
What the sources say
- Disputedcites [159] 159. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursode- oxycholic acid. Gastroenterology. 2015;148:751-761:e8. 160 sourceExperimental — accuracy not yet measured
The Study Design and Abstract describe a three-month phase 2 randomized trial, but patients received 10 mg or 50 mg OCA—not 25 mg—and 59 patients were dosed, not 165. The Results (Primary Endpoint) report ALP reductions of 53.9% and 37.2% in the OCA groups versus 0.8% with placebo, contrary to the claimed 21%–25% versus 3%. Page numbers were not provided in our copy. (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
plaindirectn = 165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“The etiology of PBC is thought to be due to a combination of genetic risk factors and environmental triggers.(5)(6)(7)”
What the sources say
- Supportedcites [5] 5. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish G, et al. Primary biliary cirrhosis in monzygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology. 2004;127:485-492. source
The opening section (p. 1) explicitly describes growing evidence that genetic susceptibility and environmental factors interact in PBC. The Discussion (p. 6) says the twin findings suggest a major genetic role and do not rule out environmental factors as triggers, consistent with the citing sentence’s qualified wording. (LLM, conf=0.94)
- Supportedcites [6] 6. Shin S, Moh IH, Woo YS, Jung SW, Kim JB, Park JW, et al. Evidence from a familial case suggests maternal inher- itance of primary biliary cholangitis. World J Gastroenterol. 2017;23:7191-7197. source
The Abstract describes environmental exposures interacting with the epigenome in genetically susceptible individuals. The ‘Epigenetics in Cholangiopathy’ section also reports genetic risk loci for PBC and environmental associations with PBC. Together, these support the citing sentence’s qualified account of its etiology; page numbers were not provided in our copy. (LLM, conf=0.90)
- Supportedcites [7] 7. Cheung AC, LaRusso NF, Gores GJ, Lazaridis KN. Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis. Semin Liver Dis. 2017;37:159-174. source
The cholangiopathy section reports genetic risk loci for PBC and environmental associations with its development, including smoking, recurrent urinary tract infections, and hair-dye use. The Abstract also describes an interplay between environmental exposures and the epigenome in genetically susceptible individuals. Together, these support the citing sentence’s qualified account of PBC etiology; page numbers were not provided in our copy. (LLM, conf=0.87)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All of these studies provide evidence of progressive disease in a substantial proportion of patients, with between 36% and 89% becoming symptomatic during average follow-up periods ranging from 4.5 to 17.8 years and a median time from diagnosis to the appearance of symptoms between 2 and 4.2 years.”
What the sources say
- Not checked — no full text of the sourcecites [44] 44. Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology. 1977;72:1204-1207. source
- Not checked — no full text of the sourcecites [45] 45. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 1994;20:707-713. source
- Partly supportedcites [46] 46. Mitchison HC, Lucey MR, Kelly PJ, Neuberger JM, Williams R, James OF. Symptom development and prognosis in primary biliary cirrhosis: a study in two centers. Gastroenterology. 1990;99:778-784. sourceExperimental — accuracy not yet measured
The Abstract reports that 19 of 70 patients at Freeman Hospital and 15 of 25 at King's College Hospital developed symptoms—34 of 95 patients, or about 36%. The Results give a median follow-up of 69 months for initially asymptomatic patients. This study supports the lower symptom-development figure, but does not itself report 89% or average follow-up spanning 4.5 to 17.8 years; those figures in the citing sentence refer to the studies collectively. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“AMA is a highly disease-specific autoantibody (8) that targets the lipoic acid present on the 2-oxo-acid dehydrogenase complexes located on the inner mitochondrial membrane.(9)”
What the sources say
- Not checked — no full text of the sourcecites [8] 8. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138:3525-3531. source
- Partly supportedcites [9] 9. Moteki S, Leung PS, Dickson ER, Van Thiel DH, Galperin C, Buch T, et al. Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. Hepatology. 1996;23:436-444. sourceExperimental — accuracy not yet measured
Citation (9) is attached to the targeting and location clause, not the disease-specificity clause cited to (8). The Abstract identifies E2 subunits of 2-oxo-acid dehydrogenase complexes as AMA targets, and the epitope-mapping discussion places a recognized epitope in OGDC-E2’s lipoic-acid-binding region. It does not establish that AMA targets lipoic acid itself or that the complexes are located on the inner mitochondrial membrane; the discussion also says lipoic acid’s presence did not affect antibody binding to BCOADC-E2. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Environmental risks have been suggested by several large case-control cohort studies that have found associations with urinary tract infections, reproductive hormone replacement, nail polish, and past cigarette smoking.(22)(23)(24)”
What the sources say
- Partly supportedcites [22] 22. Lammert C, Nguyen DL, Juran BD, Schlicht E, Larsen JJ, Atkinson EJ, et al. Questionaire based assessment of risk factors for primary biliary cirrhosis. Dig Liver Dis. 2013;45:589-594. sourceExperimental — accuracy not yet measured
The Results (Medical History; Health, Lifestyle, and Environmental Exposures; page unavailable) associate multiple urinary tract infections and a history of regular cigarette smoking with PBC. The Results (Gynecologic and Reproductive History; page unavailable) report similar hormone-replacement-therapy use in cases and controls, and no passage found supports an association with nail polish. The source therefore supports only part of the list attributed to it. (LLM, conf=0.89)
- Supportedcites [23] 23. Prince MI, Ducker SJ, James OF. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59:508-512. source
The Multivariable Results report significant associations between PBC and a history of urinary tract infection, smoking, hormone replacement therapy, and frequency of nail-polish use. The study compared 1,032 patients with PBC against matched controls; its Discussion cautions that the nail-polish association was small. (LLM, conf=0.94)
- Supportedcites [24] 24. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194-1202. source
The Multivariable Results report significant associations between PBC and a history of urinary tract infection, smoking, hormone replacement therapy use, and frequency of nail polish use. The study compares 1,032 patients with matched controls; the Discussion cautions that the nail-polish association is small. (LLM, conf=0.94)
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite progress, only an estimated 15% of the variability of the disease has been accounted for by genetic studies.(21)”
What the sources say
- Partly supportedcites [21] 21. Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2012;44:1137-1141. sourceExperimental — accuracy not yet measured
The paper’s passage on HLA associations (indexed under Abstract; page unavailable) says the identified variants explain 16.2% of estimated PBC heritability, close to the cited 15%. It distinguishes that share of heritability from the share of total disease-liability variance: the SNPs and HLA types explain 4.9% and 1.4% of liability variance, respectively. The claim does not preserve that distinction. (LLM, conf=0.89)
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Primary Biliary Cholangitis (PBC) is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology.”
What the sources say
- Supportedcites [1] 1. Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DEJ, Lindor K, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Clin Res Hepatol Gastroenterol. 2015;39:e57-e59. source
In the main text (page unavailable), the paper calls antimitochondrial antibodies PBC’s classic serologic hallmark and describes inflammatory damage to small bile ducts. It also groups PBC with immune-mediated biliary diseases, supporting the citing sentence’s characterization. (LLM, conf=0.89)
- Not matchedcites [2] 2. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Policies: The Explicit Approach. Philadelphia, PA: American College of Physicians; 1992.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [3] 3. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600-1609. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a large, international meta-analysis including 4,845 patients, UDCAtreated individuals had significantly improved transplant-free survival at 5, 10, and 15 years compared with nontreated individuals (90%, 78%, and 66% versus 79%, 59%, and 32%, respectively).(77)”
What the sources say
- Supportedcites [77] 77. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338-1349 e5; quiz e15. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirectn = 4,845- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
- It may state two separate claims as one. 60
- Probably not a substantial claim. 16
- The quote only partly states this claim. 1
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
What the sources say
- Disputedcites [160] 160. Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, et al. A randomized trial of obeti- cholic acid monotherapy in patients with primary biliary chol- angitis. Hepatology. 2018;67:1890-1902. 161 sourceExperimental — accuracy not yet measured
The Safety and Side Effects section confirms that pruritus was the most common adverse event, but reports discontinuation due to pruritus in 10% of the 10-mg group and 1% of the 5–10-mg group. This trial had no 50-mg arm; the 38% figure is the incidence of pruritus in the placebo group, not a discontinuation rate. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The indirect immunofluorescence method has the lowest sensitivity, with over 15% of AMA-negative sera by indirect immunofluorescence showing reactivity to MIT3, a combination of three mitochondrial antigens.(87)”
What the sources say
- Could not verifycites [87] 87. Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, et al. Overcoming a "probable" diagnosis in antimitochon- drial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clin Rev Allergy Immunol. 2012;42:288-297. sourceExperimental — accuracy not yet measured
The indexed copy contains an IRIS repository listing and a PDF link, but no passage from the paper addressing assay sensitivity. Searches for MIT3, indirect immunofluorescence, and the claimed 15% figure found no relevant passage, so the claim cannot be checked against our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The GLOBE score was developed from a retrospective cohort of 2,488 UDCA-treated patients and validated by a second cohort of 1,631 European and North American patients.(74)”
What the sources say
- Supportedcites [74] 74. Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with pri- mary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804-1812:e4. source
Statistical Analysis reports a derivation cohort of 2,488 patients and a separate validation cohort of 1,631, randomly split from the study population. Study Population and Design identifies the participants as UDCA-treated patients drawn from centers in North America and Europe. The validation cohort was a second group from the same database, not an independently recruited cohort. (LLM, conf=0.91)
plainn = 2,488- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to the high concordance among monozygotic twins compared with dizygotic twins with PBC (5) , the strong association with human leukocyte antigen alleles, which vary by ethnicity, supports a genetic cause of inherited risk.(12)(13)(14)(15)(16)(17)(18)(19)(20)”
What the sources say
- Supportedcites [5] 5. Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish G, et al. Primary biliary cirrhosis in monzygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology. 2004;127:485-492. source
The Results (p. 1) report PBC concordance in five of eight monozygotic twin pairs and none of eight dizygotic pairs; the Discussion (p. 6) says this suggests a major genetic role. In the citing sentence, this paper is citation (5) for the twin comparison. The HLA assertion has separate citations and is not attributed to this source. (LLM, conf=0.94)
- Supportedcites [12] 12. Juran BD, Hirshfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q1, multiple independent associ- ations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet. 2012;21:5209-5221. source
The citation to this paper is attached to the HLA portion of the sentence, not the twin-concordance statement, which has a separate citation. In “Identification of multiple independent association signals at four PBC risk loci” (p. 5), the paper reports strong HLA class II allele associations with PBC and substantial allele-frequency differences between its Italian and Canadian/US cohorts. It says the associations’ direction and magnitude were generally consistent across those cohorts. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [13] 13. Johnson PJ, Qin S, Park JW, Poon RTP, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: re- sults from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517-3524. source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although AMA-negative PBC patients are nearly identical to AMA-positive PBC patients, minor differences have been noted, including a higher prevalence of antinuclear and anti-smooth muscle antibodies and lower serum IgM levels.(111)(112)(113)”
What the sources say
- Supportedcites [111] 111. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol. 1995;90:247-249. 112 source
The discussion passage under “PBC=primary biliary cirrhosis” states that AMA-all negative patients were more likely than controls to have antinuclear and smooth muscle antibodies and had lower serum IgM. The Results passage also reports higher antibody prevalence in the AMA-negative group. Page numbers are not provided for these passages. (LLM, conf=0.94)
- Supportedcites [112] 112. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut. 1994;35:260-265. 113 source
The paper’s discussion states that, compared with AMA-positive controls, AMA-all-negative patients were more likely to have antinuclear and smooth muscle antibodies and had lower serum IgM concentrations. The Results section also reports higher antibody prevalence in the AMA-negative group. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [113] 113. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical fea- tures and clinical course of antimitochondrial antibody-pos- itive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090-1095. 114 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A number of studies have shown the benefit of UDCA in this context.(58)(59)(60)(61)(62)(63) Individual studies have demonstrated consistent evidence of improved liver biochemistries.”
What the sources say
- Supportedcites [58] 58. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Double- blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149-1156. sourceExperimental — accuracy not yet measured
The introductory passage indexed under Materials and Methods (page unavailable) describes several randomized trials of UDCA in PBC and reports biochemical improvement. A later passage indexed under Additional information (page unavailable) says longer-term follow-up studies found that improvements in liver biochemistries could be sustained. (LLM, conf=0.88)
- Supportedcites [59] 59. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 1996;110:1515-1518. sourceExperimental — accuracy not yet measured
The paper’s opening section reports that multiple UDCA trials in patients with PBC found improvements in biochemical measures of cholestasis. The Discussion likewise describes favorable biochemical effects across published trials, while noting that individual patients’ responses vary. (LLM, conf=0.91)
- Supportedcites [60] 60. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130:715-720. source
The opening passage reports that several UDCA trials in patients with PBC, including six large trials, all found improvement in biochemical cholestasis. The Discussion likewise says most published trials found favorable effects on biochemical parameters, while distinguishing these from less certain survival benefits. (LLM, conf=0.92)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fatigue is the most common symptom in PBC; it has been found in 50% to 78% of patients and has a significant negative impact on quality of life.(95)(96)”
What the sources say
- Partly supportedcites [95] 95. Newton JLJD. Modafinil is effective treatment for excessive daytime somnolence and fatigue in primary biliary cirrhosis [Abstract]. Hepatology. 2006;44:628A. sourceExperimental — accuracy not yet measured
The Associations Between NHP Scores and the Characteristics of PBC section reports a significant association between fatigue and worse overall quality of life. The Discussion says fatigue was the finding most often associated with quality-of-life subscores, not that it was the most common symptom; it gives a prevalence range of 8%–80% across prior studies, not 50%–78%. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [96] 96. Poupon RE, Chretien Y, Chazouilleres O, Poupon R, Chwalow J. Quality of life in patients with primary biliary cir- rhosis. Hepatology. 2004;40:489-494. sourceExperimental — accuracy not yet measured
The Associations Between NHP Scores and the Characteristics of PBC section reports a significant association between fatigue and worse overall quality of life. The Discussion calls fatigue the finding most often associated with quality-of-life scores, not the most common symptom, and reports prevalence across prior studies as 8%–80%, not 50%–78%. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A PBC/AIH overlap syndrome may also refer to patients with PBC followed sequentially by AIH or, less commonly, AIH followed by PBC.(119)(120)(121)”
What the sources say
- Not checked — no full text of the sourcecites [119] 119. Efe C, Ozaslan E, Heurgue-Berlot A, Kav T, Masi C, Purnak T, et al. Sequential presentation of primary biliary cirrho- sis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2014;26:532-537. 120 source
- Supportedcites [120] 120. Gossard AA, Lindor KD. Development of autoimmune hepa- titis in primary biliary cirrhosis. Liver Int. 2007;27:1086-1090. 121 source
The Frequency and Baseline Characteristics section identifies both sequential forms of PBC-AIH overlap syndrome: 12 patients developed AIH after PBC, while 5 developed PBC after AIH. The smaller second group supports the claim that AIH followed by PBC was less common in this cohort. (LLM, conf=0.94)
- Supportedcites [121] 121. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85-90. 122 source
The Results section (“Frequency and Baseline Characteristics”) includes sequential cases under PBC-AIH overlap syndrome: 12 patients developed AIH after PBC, while 5 developed PBC after AIH. This supports both sequences and the claim that the latter was less common in this cohort; page numbers were not supplied in our copy. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The symptoms of PBC significantly impair quality of life (182) and do not typically improve with UDCA or OCA treatment.”
What the sources say
- Supportedcites [182] 182. Mells GF, Pells G, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, et al. Impact of primary biliary cirrho- sis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58:273-283. 183 source
Citation (182) is attached to the claim that PBC symptoms significantly impair quality of life, not to the subsequent treatment claim. The Results report substantial quality-of-life impairment among PBC patients, and the Discussion says symptoms often had a dramatic impact on life quality. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Doubling the dose of UDCA and adding colchicine, methotrexate, or silymarin have not been found to be of benefit over and beyond that achieved with UDCA alone.(163,178,179)”
What the sources say
- Not matchedcites [163] 163. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrex- ate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology. 2004;39:915-923. 164
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [178] 178. Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;32:897-900. 179 source
- Partly supportedcites [179] 179. Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am J Gastroenterol. 2001;96:3152-3157. 180 sourceExperimental — accuracy not yet measured
The Discussion (page not specified) says adding colchicine showed no benefit for patients with a suboptimal response to UDCA. It also reports negative results from larger controlled trials of methotrexate, while acknowledging biochemical improvement in a few selected patients. Our copy does not establish the claimed lack of benefit from doubling the UDCA dose or adding silymarin. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, patients with earlier histologic stage usually respond more favorably to UDCA than patients with advanced disease, although patients with advanced disease may benefit in survival or avoid liver transplantation with this therapy.(63)”
What the sources say
- Partly supportedcites [63] 63. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cir- rhosis. Gastroenterology. 1997;113:884-890. sourceExperimental — accuracy not yet measured
The Discussion suggests UDCA might be less efficacious when introduced later in disease, but does not establish that earlier histologic stages usually respond more favorably. For the outcome this study measured, survival free of transplantation, the subgroup analysis found a significant benefit at stage IV but not at stages I–II or III (Figure 3, Discussion). The claim that patients with advanced disease may benefit is supported. (LLM, conf=0.87)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with the phase 2 studies, pruritus was the most common adverse event, but it was less common in patients undergoing dose titration starting at 5 mg/day.”
What the sources say
- Supportedcites [161] 161. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeti- cholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-643. 162 source
The Trial Design section (p. 2) identifies this as a phase 3 trial and says the 5–10 mg group started at 5 mg daily, with an increase to 10 mg if appropriate. The Discussion (p. 10) calls pruritus the most common adverse event and reports a lower incidence in that group (56%) than in the group starting at 10 mg (68%). (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“After 1 year, this primary endpoint was met by 46% of patients in the titration group, 47% in the 10 mg/day group, and 10% of patients in the placebo group.(161)”
What the sources say
- Supportedcites [161] 161. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeti- cholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631-643. 162 source
The Primary End Point section (p. 4) reports that at month 12 the endpoint was met by 46% in the 5–10-mg titration group, 47% in the 10-mg group, and 10% in the placebo group. These are the figures and time point attributed to the source in the citing sentence. (LLM, conf=0.95)
plainn = 210- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, UDCA therapy does not improve fatigue, pruritus, associated bone disease, or autoimmune features found in association with PBC.(69,89,153,154)”
What the sources say
- Not checked — no full text of the sourcecites [69] 69. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esoph- ageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137-1140. source
- Could not verifycites [89] 89. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology. 1999;29:1007-1012. sourceExperimental — accuracy not yet measured
The paper’s ‘Effect of UDCA Therapy on Histological Progression’ and ‘UDCA Therapy and Histology Progression’ sections assess liver-biopsy findings, not whether UDCA improves fatigue, pruritus, bone disease, or associated autoimmune features. Searches for those symptoms and conditions found no passage addressing the claimed lack of improvement; page numbers were not supplied for the passages. (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [153] 153. Balan V, Dickson ER, Jorgensen RA, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc. 1994;69:923-929. 154 source
- Not matchedcites [154] 154. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: Does ursodeoxy- cholic acid make a difference? Hepatology. 1995;21:389-392. 155
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although uncommon, drug-induced liver injuries-sometimes progressing to acute liver failure, hemolysis, renal impairment, and alteration in drug metabolism-have all been reported with rifampicin use such that use is avoided in patients with bilirubin levels greater than 2.5 mg/dL, with close follow-up warranted.(195,199)”
What the sources say
- Not checked — no full text of the sourcecites [195] 195. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet. 1989;1:574-576. 196 source
- Partly supportedcites [199] 199. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunc- tion with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436-439. 200 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Etidronate was ineffective compared with placebo”
What the sources say
- Could not verifycites [239] 239. Guanabens N, Monegal A, Cerda D, Muxi A, Gifre L, Peris P, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with pri- mary biliary cirrhosis. Hepatology. 2013;58:2070-2078. 240 sourceExperimental — accuracy not yet measured
The introduction mentions trials of etidronate in patients with primary biliary cirrhosis, including bisphosphonate comparisons with placebo, but gives no result for etidronate versus placebo. The Results report outcomes for ibandronate and alendronate only. Searches for etidronate’s effectiveness versus placebo found no passage establishing the claimed lack of benefit. (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the itch in cholestasis does not appear to be histamine-related, antihistamines may be beneficial in patients with cholestasis, probably because of their sedative properties.(214,215)”
What the sources say
- Partly supportedcites [214] 214. Rishe E, Azarm A, Bergasa NV. Itch in primary bili- ary cirrhosis: a patients' perspective. Acta Derm Venereol. 2008;88:34-37. 215) sourceExperimental — accuracy not yet measured
The indexed Abstract (page unavailable) reports that patients with primary biliary cirrhosis most commonly associated antihistamines with itch relief. It does not establish that cholestatic itch is unrelated to histamine or attribute the reported relief to antihistamines’ sedative properties. (LLM, conf=0.84)
- Not matchedcites [215] 215. Greaves MW. Antihistamines in dermatology. Skin Pharmacol Physiol. 2005;18:220-229. 216
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This helps detect patients who are inadequate responders to UDCA after 12 months of therapy, lack of adherence, and the rare patients who go on to develop AIH.(121,135,224,225)”
What the sources say
- Supportedcites [121] 121. Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85-90. 122 source
This source supports the AIH portion of the multiply cited sentence. In the Results (pp. 85–90), 12 of 282 patients with PBC developed AIH during follow-up; the Clinical and Laboratory Assessments section describes examinations at follow-up visits, and the Discussion cautions that the condition should not be missed. The paper does not establish the separate claims about 12-month UDCA response or adherence. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [135] 135. Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syn- drome. J Hepatol. 2006;44:400-406. 136 source
- Not checked — no full text of the sourcecites [224] 224. Colombato LA, Alvarez F, Cote J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary bili- ary cirrhosis and autoimmune hepatitis? Gastroenterology. 1994;107:1839-1843. 225 source
- Not checked — no full text of the sourcecites [225] 225. Weyman RL, Voigt M. Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: a case report and review of the literature. Am J Gastroenterol. 2001;96:585-587. 226 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“both drugs have a comparable efficacy and safety profile.(239)”
What the sources say
- Supportedcites [239] 239. Guanabens N, Monegal A, Cerda D, Muxi A, Gifre L, Peris P, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with pri- mary biliary cirrhosis. Hepatology. 2013;58:2070-2078. 240 source
The Discussion reports that both drugs increased bone mass and were well tolerated in postmenopausal women with primary biliary cirrhosis and osteoporosis or severe osteopenia. The Results report similar overall adverse-event rates, and the study found no significant difference between groups in lumbar-spine bone-density gains. The comparison is supported for the population studied. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Some 20% to 30% of patients with PBC who undergo transplantation develop recurrent disease over 10 years, and up to 50% do so by 20 years of follow-up.”
What the sources say
- Not checked — no full text of the sourcecites [256] 256. Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune dis- ease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(Suppl 2):S25-S34. 257 source
- Partly supportedcites [257] 257. Bosch A, Dumortier J, Maucort-Boulch D, Scoazec JY, Wendum D, Conti F, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol. 2015;63:1449-1458. 258 sourceExperimental — accuracy not yet measured
The Recurrence Rate section reports recurrent PBC in 17% of patients using strict histologic criteria; Table 4 gives an estimate of 26% using expanded criteria. Neither is a 10-year estimate: the Patient Groups section reports mean follow-up of 4.7 years and a maximum of 13.8 years. The paper does not support the claim of up to 50% recurrence by 20 years. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several randomized trials, combined analyses, and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation.(53,(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)”
What the sources say
- Not checked — no full text of the sourcecites [53] 53. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibro- sis progression in primary biliary cirrhosis. Hepatology. 2000;32:1196-1199. source
- Not matchedcites [56] 56. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histo- logical progression in primary biliary cirrhosis. Hepatology. 1999;29:644-647.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [57] 57. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, place- bo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759-66. source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The bilirubin level is the best predictor of survival and is the most important component in all mathematical models of prognosis in PBC.(71,76)”
What the sources say
- Not checked — no full text of the sourcecites [71] 71. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1-7. source
- Not checked — no full text of the sourcecites [76] 76. Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology. 1989;10:846-850. source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The UK-PBC score involved a cohort of 3,165 patients and found that serum ALP, amino transferases, and bilirubin after 12 months of therapy-as well as albumin and platelets at baseline-predicted the risk of a liver transplant or liver-related death occurring within 5, 10, or 15 years.(75)”
What the sources say
- Not matchedcites [75] 75. Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930-950.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelationaln = 3,165- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Compared with AMA-positive PBC patients, AMAnegative PBC patients have more nonhepatic autoimmune conditions (114)(115) and worse health-related quality of life in social and emotional domains.(116)”
What the sources say
- Not checked — no full text of the sourcecites [114] 114. Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utiliza- tion of clinical data when patients applied to receive public financial aid. J Epidemiol. 2006;16:30-34. 115 source
- Not checked — no full text of the sourcecites [115] 115. Juliusson G, Imam M, Bjornsson ES, A. TJ, Lindor KD. Long- term outcomes in antimitochondrial antibody negatve primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745-752. 116 source
- Not checked — no full text of the sourcecites [116] 116. Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, Rigopoulou EI, Kostrzewa K, Norman GL, et al. Assessment of health related quality of life in polish patients with primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2016;40:471-479. 117 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“These criteria have been met in 1% to 14.2% of PBC patients, with higher rates found in Hispanic PBC patients.(128)(129)(130)(131)(132)(133)”
What the sources say
- Not checked — no full text of the sourcecites [128] 128. Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999;29:1078-1084. 129 source
- Not checked — no full text of the sourcecites [129] 129. Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, et al. Primary biliary cirrhosis with additional fea- tures of autoimmune hepatitis: response to therapy with ur- sodeoxycholic acid. Hepatology. 2002;35:409-413. 130 source
- Not checked — no full text of the sourcecites [130] 130. Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007;31:17-25. 131 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The proposed mechanisms of action of UDCA are multiple and include choleretic, cytoprotective, anti-inflammatory, and immunomodulatory properties.(141)”
What the sources say
- Not checked — no full text of the sourcecites [141] 141. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revis- ited. Hepatology. 2002;36:525-531. 142 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, the International Autoimmune Hepatitis Group score was designed for the diagnosis of AIH with the exclusion of other liver diseases, including PBC, and therefore positive points are given for the absence of factors unrelated to a diagnosis of PBCe.g., viral hepatitis and alcohol abuse-and negative scores are given for AMA and/or biochemical/histologic features of biliary disease.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These patients may no longer have AMA seropositivity, and liver histology becomes more typical of AIH that responds to immunosuppressive therapy.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“UDCA is widely used and has demonstrated the ability to produce a reduction in need for liver transplantation for PBC.(144)”
What the sources say
- Not checked — no full text of the sourcecites [144] 144. Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5:1313-1315. 145 source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“However, treatment response to UDCA appears similar in AMA-negative and AMA-positive PBC patients, and whether there are differences in clinical outcomes has not been resolved.(113,115)”
What the sources say
- Not checked — no full text of the sourcecites [113] 113. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical fea- tures and clinical course of antimitochondrial antibody-pos- itive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090-1095. 114 source
- Not checked — no full text of the sourcecites [115] 115. Juliusson G, Imam M, Bjornsson ES, A. TJ, Lindor KD. Long- term outcomes in antimitochondrial antibody negatve primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745-752. 116 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The wide variability among studies may be due to a variety of genetic and environmental factors as well as the nonuniform collection of biochemical, serological, immunological, and histological data.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“However, an estimated 50% of patients in either group had received treatment with UDCA, and some in both groups had received a variety of other therapies.”
What the sources say
- Not checked — no full text of the sourcecites [134] 134. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007;102:1244-1250. 135 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Some meta-analyses have questioned these results.(142) Often, these meta-analyses include studies of short duration and those that have used what is now known to be an inadequate dose of UDCA.(143)”
What the sources say
- Not checked — no full text of the sourcecites [142] 142. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cir- rhosis: a meta-analysis. Lancet. 1999;354:1053-1060. 143 source
- Not checked — no full text of the sourcecites [143] 143. Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799-1807. 144 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Early studies reported that pruritus (itching) occurs in 20% to 70% of patients with PBC.It is now less common because of the growing number of patients with PBC who are diagnosed in the early, asymptomatic phase.(100)(101)(102)”
What the sources say
- Not checked — no full text of the sourcecites [100] 100. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865-870. 101 source
- Not checked — no full text of the sourcecites [101] 101. Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003;1:297-302. 102 source
- Not checked — no full text of the sourcecites [102] 102. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis. 2003;7:779-794. 103 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Right upper quadrant pain is found in approximately 17% of patients with PBC.It is typically nonspecific in character, not progressive in nature, not well correlated with disease stage or hepatomegaly, and often disappears spontaneously.Its etiology is unknown.(108)”
What the sources say
- Not checked — no full text of the sourcecites [108] 108. Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain asso- ciated with primary biliary cirrhosis. Am J Gastroenterol. 1994;89:1840-1843. 109
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“This score was subsequently revised (122) and, when applied to PBC cohorts, revealed that less than 1% of PBC patients met definite AIH diagnostic criteria, while 8% to 19% met probable AIH criteria.(123)(124)”
What the sources say
- Not checked — no full text of the sourcecites [122] 122. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938. 123 source
- Not checked — no full text of the sourcecites [123] 123. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of auto- immue hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002;97:1191-1197. 124 source
- Not checked — no full text of the sourcecites [124] 124. Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, et al. Clinical and pathological characteristics of the auto- immune hepatitis and primary biliary cirrhosis overlap syn- drome. J Gastroenterol Hepatol. 2004;19:699-706. 125 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“UDCA with or without immunosuppressive therapy has been used, but no clear consensus on optimal therapy for these patients exists.(129)(130)(134)(135)”
What the sources say
- Not checked — no full text of the sourcecites [129] 129. Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, et al. Primary biliary cirrhosis with additional fea- tures of autoimmune hepatitis: response to therapy with ur- sodeoxycholic acid. Hepatology. 2002;35:409-413. 130 source
- Not checked — no full text of the sourcecites [130] 130. Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007;31:17-25. 131 source
- Not checked — no full text of the sourcecites [134] 134. Silveira MG, Talwalkar JA, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007;102:1244-1250. 135 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Budesonide may be helpful, although this is controversial.(180)”
What the sources say
- Not matchedcites [180] 180. Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ur- sodeoxycholic acid. Hepatology. 2000;31:318-323. 181
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
In the paper
“A 5-pound weight gain over the first year of therapy has been reported and is not progressive.(155)”
What the sources say
- Not checked — no full text of the sourcecites [155] 155. Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ur- sodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2003;37:183-185. 156 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Altered serotonin neurotransmission may mediate fatigue in chronic liver disease (183) ; however, ondansetron, an antagonist to serotonin receptor, did not relieve fatigue in a clinical trial.(184)”
What the sources say
- Not matchedcites [183] 183. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet. 1999;354:397. 184
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [184] 184. Theal JJ, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fa- tigue. Hepatology. 2005;41:1305-1312. 185 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Modafinil, a stimulant used for narcolepsy, was originally reported to lessen fatigue in PBC in open-label studies.(186,187) However, a subsequent placebo-controlled trial failed to show benefit.(188)”
What the sources say
- Not checked — no full text of the sourcecites [186] 186. Kaplan MM, Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med. 2005;143:546-547. 187 source
- Not checked — no full text of the sourcecites [187] 187. Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary bili- ary cirrhosis. Aliment Pharmacol Ther. 2007;25:471-476. 188 source
- Not checked — no full text of the sourcecites [188] 188. Silveira MG, Gossard AA, Stahler AC, Jorgensen RA, Petz JL, Ali AH, et al. A randomized, placebo-controlled clini- cal trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Am J Ther. 2017;24:e167-e76. 189 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Finally, fibrates can cause elevation of transaminases, which is also typically reversible.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Improvement in liver tests are typically observed within a few weeks, and 90% of the improvement usually occurs within 6 to 9 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The use of UDCA has been associated with a reduction of serum low-density lipoprotein cholesterol levels, a reduced risk of developing varices, and slower histologic progression.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This is typically reversible and not associated with a decline in glomerular filtration rate, but it is attributed to an increase in creatinine production.(167)”
What the sources say
- Not checked — no full text of the sourcecites [167] 167. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99:3C-18C. 168 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Furthermore, improvement in pruritus and beneficial effects on markers of fibrosis were also observed.”
What the sources say
- Not checked — no full text of the sourcecites [94] 94. Corpechot C, Chazouillères O, Rousseau A, Guyader D, Habersetzer F, Mathurin P, et al. A 2-year multicenter, double-blind, randomized, placebo-controlled study of be- zafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxy- cholic acid therapy (Bezurso). J Hepatol. 2017;66:S89. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
What the sources say
- Not checked — no full text of the sourcecites [156] 156. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6α-ethyl-chenodeoxycholic acid (6- ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569-3572. 157 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, use of fibrates can be associated with myalgias and heartburn, and an elevation in serum creatinine is frequently observed.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Older patients and those with lower fibrosis scores were more likely to respond.”
What the sources say
- Not checked — no full text of the sourcecites [166] 166. Reig A, Sese P, Pares A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with subopti- mal ursodeoxycholic acid response. Am J Gastroenterol. 2018;113:49-55. 167 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These comorbidities both promote disease progression and may put the individual at risk of not being accepted for a liver transplant should the latter become necessary.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Estrogens promote cholestasis, so oral contraceptive pills and estrogen supplements may induce or worsen pruritus.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“Intractable fatigue is not a valid indication for liver transplantation because fatigue usually persists post transplant.(189)”
What the sources say
- Not checked — no full text of the sourcecites [189] 189. Carbone M, Bufton S, Monaco A, Griffiths L, Jones DE, Neuberger JM. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol. 2013;59:490-494. 190 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At this time, there is no recommended therapy for the fatigue resulting from PBC.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A short second stage of labor is optimal because the Valsalva maneuver may precipitate variceal hemorrhage.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“It is not known which substance in the gut they may be binding to that leads to improved cholestatic itching, and clinical trials proving their efficacy are limited, but they have a long track record of clinical use.(190,191)”
What the sources say
- Not checked — no full text of the sourcecites [190] 190. Datta DV, Sherlock S. Cholestyramine for long term re- lief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50:323-332. 191 source
- Not checked — no full text of the sourcecites [191] 191. Van Itallie TB, Hashim SA, Crampton RS, Tennent DM. The treatment of pruritus and hypercholesteremia of pri- mary biliary cirrhosis with cholestyramine. N Engl J Med. 1961;265:469-474. 192 source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“There are limited data about fertility or infant outcome in PBC patients.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The majority of individuals currently have no symptoms referable to their liver disease when diagnosed with PBC.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This lack of symptoms makes it particularly difficult for an individual to recognize the importance of preventive strategies in PBC.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Colesevalam was not effective in a single placebo-controlled trial of cholestatic pruritus.(192) However, only patients who had already failed other resins were enrolled.”
What the sources say
- Not checked — no full text of the sourcecites [192] 192. Kuiper EM, van Erpecum KJ, Beuers U, Hansen BE, Thio HB, de Man RA, et al. The potent bile acid sequestrant cole- sevelam is not effective in cholestatic pruritus: results of a dou- ble-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:1334-1340. 193 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Sertraline, given at a dose of 75 to 100 mg, helped relieve pruritus in a single, small, placebo-controlled trial and in a retrospective case series.The effect was independent from an improvement in depression.(209)”
What the sources say
- Not checked — no full text of the sourcecites [209] 209. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666-674. 210 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Phenobarbital can improve cholestatic pruritus but is a strong sedative that worsens or initiates fatigue, increases vitamin D deficiency, and has been associated with troublesome gingival hyperplasia.(213)”
What the sources say
- Not checked — no full text of the sourcecites [213] 213. Bloomer JR, Boyer JL. Phenobartial effectis in cholestatic liver disease. Ann Intern Med. 1975;82:310-317. 214 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Patients with PBC may develop portal hypertension as a result of biliary cirrhosis or, in the precirrhotic stage of the disease, in association with nodular regenerative hyperplasia.(232,233)”
What the sources say
- Not matchedcites [232] 232. Kew MC, Varma RR, Santos HAD, Scheuer PJ. Portal hyper- tension in primary biliary cirrhosis. Gut. 1971;12:830-834. 233
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [233] 233. Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic bili- ary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol. 2006;30:1454-1461. 234 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Similarly, during pregnancy, itching may become severe even early on in the pregnancy, and it may fail to resolve completely after delivery in patients with PBC.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Ondansetron, a serotonin antagonist, was initially reported to decrease cholestatic itch but was later found to be no better than placebo in more rigorous trials.(210)(211)(212)”
What the sources say
- Not checked — no full text of the sourcecites [210] 210. Raderer M, Muller C, Scheithauer W. Ondansetron for pruri- tus due to cholestasis. N Engl J Med. 1994;330:1540. 211 source
- Not checked — no full text of the sourcecites [211] 211. Schworer H, Ramadori G. Improvement of cholestatic pruri- tus by ondansetron. Lancet. 1993;341:1277. 212 source
- Not checked — no full text of the sourcecites [212] 212. Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology. 2007;54:1196-1199. 213
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Patients with dry mouth are at increased risk of dental caries and should receive regular professional dental cleanings and check-ups.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Treatment with beta blockers is safe in pregnancy.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“This has been challenged by a meta-analysis that identified a pooled risk of 1.57 (95% CI, 1.21-2.06)(247)”
What the sources say
- Not checked — no full text of the sourcecites [247] 247. Ungprasert P, Wijarnpreecha K, Ahuja W, Spanuchart I, Thongprayoon C. Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observa- tional studies. Hepatol Res. 2015;45:1055-1061. 248 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Long-term immunosuppression with a cyclosporine-based regimen seems to be associated with reduced incidence of recurrent PBC, but this is not proven.(259)”
What the sources say
- Not checked — no full text of the sourcecites [259] 259. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, et al. Long-term survival and im- pact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007;13:1236-1245. 260 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Osteopenia may worsen for the first 6 months after transplantation, but bone mineral density returns to baseline after 12 months and improves thereafter.(254)”
What the sources say
- Not checked — no full text of the sourcecites [254] 254. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 1991;14:296-300. 255 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Fatigue improves in a subset of patients with PBC, but moderate to severe fatigue continues to affect nearly half of patients 2 years after liver transplantation.(189)”
What the sources say
- Not checked — no full text of the sourcecites [189] 189. Carbone M, Bufton S, Monaco A, Griffiths L, Jones DE, Neuberger JM. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol. 2013;59:490-494. 190 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the same study, the 1-, 3-, 5-, and 10-year graft survival rates were 85%, 80%, 78.1%, and 71.9%, and the 1-, 3-, 5-, and 10-year patient survival rates were 90.2%, 86.7%, 84.4%, and 79%, respectively.(253)”
What the sources say
- Not checked — no full text of the sourcecites [253] 253. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver trans- plantation based on etiology of liver disease. Transplantation. 2013;95:755-760. 254 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Hormone replacement therapy has led to some improvement in bone mineral density, but these agents are seldom used because of safety concerns.(243)”
What the sources say
- Not checked — no full text of the sourcecites [243] 243. Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci. 2006;51:1103-1112. 244 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Accepted treatments for sicca syndrome work equally well in patients with PBC even though they have not been studied specifically in that population.
“Although not studied specifically in patients with PBC, accepted treatments for sicca syndrome appear to work equally well in this population.”
The paper relies on this without support.
OCA was approved by the Food and Drug Administration in May 2016 for use with UDCA in PBC patients with inadequate response to at least 1 year of UDCA or as monotherapy for UDCA-intolerant patients.
“OCA was approved by the Food and Drug Administration in May 2016 to be used in combination with UDCA in patients with PBC who have inadequate response to at least 1 year of treatment with UDCA, or as monotherapy for those patients who are intolerant to UDCA.”
The paper relies on this without support.
Men and those with advanced disease are most likely to develop hepatocellular cancer.
“Men and patients with advanced disease are most apt to develop hepatocellular cancer”
The paper relies on this without support.
Hepatocellular cancer occurs at 3.9 cases per 1,000 person-years in PBC.
“which was found at a rate of 3.9 cases in 1,000 per year of follow-up.”
The paper relies on this without support.
Fat-soluble vitamin deficiency is uncommon in most PBC patients.
“Most PBC patients do not develop fat-soluble vitamin (vitamins A, D, E, and K) deficiency.”
The paper relies on this without support.
Chronic fatigue is not a transplant indication since it does not always reverse after liver transplantation.
“Chronic fatigue is not an indication for transplant because this symptom is not universally reversible after liver transplantation.”
The paper relies on this without support.
Severe, intractable pruritus is an uncommon indication for liver transplantation.
“Severe intractable pruritus is an exceptional indication for liver transplantation.”
The paper relies on this without support.
Liver transplantation indications for PBC resemble those for other chronic liver diseases.
“Indications for liver transplantation for patients with PBC are similar to those with other forms of chronic liver disease.”
The paper relies on this without support.
Platelet counts can guide the need for endoscopic surveillance.
“Platelet counts can be used to determine the need for endoscopic surveillance.”
The paper relies on this without support.
UDCA lowers LDL cholesterol and is the first-line step.
“UDCA will lower low-density lipoprotein cholesterol levels and is the initial step.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, fibrates are only approved by the FDA as lipid-lowering medications in the United States (US) and multiple countries rather than PBC treatment [7].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The AASLD notes that fibrates, including fenofibrate, may improve pruritus in PBC, based on observational studies and clinical experience, but most high-quality randomized controlled trial data specifically address bezafibrate rather than fenofibrate [7].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The AASLD notes that fenofibrate can cause transient elevations in transaminases, but not associated with any toxicity and normalize with therapy discontinuation [7].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fibrates modulate hepatic stellate cell activation; as it regulates bile acid synthesis and detoxification, and phospholipid secretion [7,38].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These effects collectively reduce cholesterol and hepatic inflammation, and it reflects by reductions in serum ALP and GGT levels [7,15,39].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, primary biliary cholangitis is characterised by persistent elevation of cholestatic liver enzymes, including alkaline phosphatase and gammaglutamyl transpeptidase (GGT), and detection of antimitochondrial antibodies or primary biliary cholangitis-specific anti-nuclear antibodies (anti-sp100 or anti-gp210).[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-invasive liver stiffness measurement (LSM) has proven useful as an alternative to invasive liver biopsy for the evaluation of liver fibrosis, and LSM using transient elastography is recommended at the time of diagnosis.3,4,55”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Histological assessment requires an adequate biopsy specimen containing at least 10-15 portal tracts obtained using a 16 g needle because the intensity of chronic non-suppurative destructive cholangitis and focal loss of bile ducts vary along the length of individual interlobular bile ducts in primary biliary cholangitis.4”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to the American Association for the Study of Liver Diseases (AASLD), ursodeoxycholic acid (UDCA) is the first-line treatment for PBC [7].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“An increase in bilirubin can occur. This has been attributed to competitive inhibition of the transporter organic-anion-transporting polypeptide, which transports both bile acids and bilirubin, among other endogenous substances [7].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Fenofibrate may cause reversible elevations in serum creatinine, likely due to increased creatinine production rather than a true decline in the glomerular filtration rate [7,42].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The AASLD considers fibrates an off-label option for PBC patients with incomplete UDCA response but advises against their use in decompensated liver disease (Child-Pugh B and C) due to lack of safety data and potential risk of hepatotoxicity [7].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“A diagnosis of primary biliary cholangitis is made if patients meet at least two of the following criteria: have biochemical evidence of chronic cholestasis, positive anti-mitochondrial antibodies in sera, and histological features compatible with primary biliary cholangitis.[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Ursodeoxycholic acid is standard-of-care treatment for primary biliary cholangitis.”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical practice guidelines from the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases (AASLD), and the Asian-Pacific Association for the Study of the Liver recommend ursodeoxycholic acid treatment (13-15 mg/kg per day) for all patients with primary biliary cholangitis and elevated cholestatic enzymes.[3][4][5]”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the liver stiffness measurement (LSM) in stratifying the risk for progression has been confirmed.3,4,55”
From Primary biliary cholangitis. (2024) · cites this paper as [4]
In the citing paper
“In PBC, UDCA is used as first-line treatment,2 66 67 but 30%–50% of patients respond insufficiently (based on biochemical criteria)”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [67]
In the citing paper
“Current guideline-recommended medical treatment options for pruritus of cholestasis include the anion exchange resin cholestyramine, the pregnane X receptor (PXR) agonist rifampicin, the opioid antagonist naltrexone, and the selective serotonin reuptake inhibitor sertraline.4,7 Efficacy or tolerability of these drugs, or both, are limited.8,9”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [7]
In the citing paper
“Patients with PBC have a significantly greater risk of osteopenia and osteoporosis than age-matched and sex-matched controls [40].”
From Bone diseases in patients with chronic liver disease (2019) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ loNg-terM FolloW-Up
“For patients with known cirrhosis with a Mayo risk score greater than 4.1 or transient elastography values of at least 7 kPa, upper endoscopy to assess for varices should be done every 2 to 3 years.”
§ HepatoCellUlar CarCiNoMa
“Upper endoscopy every 1-3 years if cirrhotic, Mayo risk score >4.1, or transient elastography shows a score ≥17 kPa*”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ liVer traNSplaNtatioN
“Alendronate is a more effective treatment than etidronate, (255) but there are no studies to confirm the longterm efficacy of any treatment.”
§ References
“255. Baldo-Enzi G, Baiocchi MR, Grotto M, Floreani AR, Zagolin M, Chiaramonte M, et al. Lipoprotein pattern and plasma lipo- protein lipase activities in patients with primary biliary cirrhosis.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ otHer aUtoiMMUNe CoNditioNS
“There are three major autoimmune diseases that have been shown in a cohort study to occur significantly more often in PBC than the age-matched and sex-matched population:”
§ otHer aUtoiMMUNe CoNditioNS
“Sjögren syndrome; calcinosis, Raynaud, esophageal dysfunction, sclerodactyly, and telangectasias (CREST); scleroderma (systemic sclerosis); and Raynaud disease.”
Citations
Cites
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Garcia‐Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017) · Hepatology · doi:10.1002/hep.28906 · Cited by 2,154
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 2,016
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 2×
“(157,158) In animal models, FXR activation has demonstrated antifibrotic and anti-inflammatory properties as well.(157) A phase 2 randomized controlled trial evaluated 3 doses of OCA (10 mg, 25 mg, and 50 mg) against placebo for 3 months in a study including 165 patients.”
BackgroundKaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 1×
“After 1 year, this primary endpoint was met by 46% of patients in the titration group, 47% in the 10 mg/day group, and 10% of patients in the placebo group.(161) Improvements in other liver chemistries and inflammatory markers were also noted in OCA-treated patients.”
BackgroundSelf-citationMartin, P., DiMartini, A., Feng, S., Brown, R., & Fallon, M. (2014) · Hepatology · doi:10.1002/hep.26972 · Cited by 1,045
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 3×
“(70) Once the Mayo model was introduced by Dickson, prognosis could be estimated without the need for biopsy.(71) Following the introduction of UDCA therapy, a series of models—which are summarized in recent reviews(72-73) and most of which were based on alkaline phosphatase (ALP) responses to treatment— ensued.”
BackgroundMethodInfluentialJohnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationBiochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 2×
“(148) Biochemical response should be assessed after 1 year of treatment with UDCA using one of many published criteria shown in Table 1.(60,77-79,149-152) When one of these binary definitions for response to UDCA is used, up to 40% of PBC patients will have an inadequate response to treatment.”
BackgroundMethodCainap, C. I., Qin, S., Huang, W., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y., Chen, P., Toh, H.-C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 634
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Self-citationNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citationGershwin, M. E., Mackay, I. R., Sturgess, A., & Coppel, R. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3525 · Cited by 557
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment
Selmi, C., Mayo, M. J., Bach, N., Ishibashi, H., Invernizzi, P., Gish, R. G., Gordon, S. C., Wright, H. I., Zweiban, B., Podda, M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.005 · Cited by 480
Self-citationGenome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.789 · Cited by 464
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Kuiper, E. M. M., Hansen, B. E., de Vries, R. A., den Ouden–Muller, J. W., van Ditzhuijsen, T. J. M., Haagsma, E. B., Houben, M. H. M. G., Witteman, B. J. M., van Erpecum, K. J., & van Buuren, H. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.003 · Cited by 460
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC
Corpechot, C., El Naggar, A., Poujol-Robert, A., Ziol, M., Wendum, D., Chazouillères, O., de Lédinghen, V., Dhumeaux, D., Marcellin, P., Beaugrand, M., et al. (2006) · Hepatology · doi:10.1002/hep.21151 · Cited by 441
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationNatural history of early primary biliary cirrhosis
Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421
Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis
Christensen, E., Neuberger, J., Crowe, J., Altman, D. G., Pópper, H., Portmann, B. C., Doniach, D., Ranek, L., Tygstrup, N., & Williams, R. L. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90213-6 · Cited by 420
Roll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417
Self-citationSafety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
Liu, X., Invernizzi, P., Lu, Y., Kosoy, R., Lu, Y., Bianchi, I., Podda, M., Xu, C., Xie, G., Macciardi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.627 · Cited by 398
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R., & Poupon, R. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 392
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Bergasa, N. V., Alling, D. W., Talbot, T. L., Swain, M. G., Yurdaydin, C., Turner, M. L., Schmitt, J. M., Walker, E. C., & Jones, E. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-3-199508010-00001 · Cited by 365
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Corpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351
Prince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Self-citationSertraline as a first-line treatment for cholestatic pruritus
Mayo, M. J., Handem, I., Saldana, S., Jacobe, H., Getachew, Y., & Rush, J. A. (2007) · Hepatology · doi:10.1002/hep.21553 · Cited by 329
Self-citationGhonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
Self-citationCorpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
A Prospective Trial of Colchicine for Primary Biliary Cirrhosis
Kaplan, M. M., Alling, D. W., Zimmerman, H. J., Wolfe, H. J., Sepersky, R. A., Hirsch, G. S., Elta, G. H., Glick, K., & Eagen, K. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152304 · Cited by 313
COMBES, B., Carithers, R. L., Maddrey, W. C., Lin, D., McDonald, M. F., Wheeler, D. E., Eigenbrodt, E. H., Muñoz, S. J., Rubin, R., Garcia-Tsao, G., et al. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 303
Self-citationOpioid peptides and primary biliary cirrhosis
Thornton, J. R., & Losowsky, M. S. (1988) · BMJ · doi:10.1136/bmj.297.6662.1501 · Cited by 300
Eastell, R., Dickson, R. E., Hodgson, S. F., Wiesner, R. H., Porayko, M. K., Wahner, H. W., Cedel, S. L., Riggs, L. B., & Krom, R. A. F. (1991) · Hepatology · doi:10.1002/hep.1840140215 · Cited by 297
Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology · doi:10.1002/hep.25748 · Cited by 291
Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9019 · Cited by 287
Self-citationA randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281
Lohse, A. W., zum Büschenfelde, K.-H. M., Franz, B., Kanzler, S., Gerken, G., & Dienes, H.-P. (1999) · Hepatology · doi:10.1002/hep.510290409 · Cited by 278
Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease
Singal, A. K., Guturu, P., Hmoud, B., Kuo, Y.-F., Salameh, H., & Wiesner, R. H. (2013) · Transplantation · doi:10.1097/tp.0b013e31827afb3a · Cited by 278
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis
The UK Primary Biliary Cirrhosis (PBC) Consortium, Liu, J. Z., The Wellcome Trust Case Control Consortium 3, Almarri, M. A., Gaffney, D. J., Mells, G. F., Jostins, L., Cordell, H. J., Ducker, S. J., Day, D. B., et al. (2012) · Nature Genetics · doi:10.1038/ng.2395 · Cited by 274
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Nakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., Nakamura, H., Komori, A., Nakamuta, M., Zeniya, M., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.08.010 · Cited by 267
Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20671 · Cited by 264
Prince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. W. (2004) · Gut · doi:10.1136/gut.2003.023937 · Cited by 261
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Shimoda, S., de Water, J. V., Ansari, A. A., Nakamura, M., Ishibashi, H., Coppel, R. L., Lake, J. R., Keeffe, E. B., Roche, T. E., & Gershwin, M. E. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4213 · Cited by 250
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
Angulo, P., Batts, K. P., Therneau, T. M., Jorgensen, R. A., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290301 · Cited by 234
Self-citationCOMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228
Self-citationImpact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study
Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology · doi:10.1002/hep.26365 · Cited by 227
Nakanuma, Y., Zen, Y., Harada, K., Sasaki, M., Nonomura, A., Uehara, T., Sano, K., Kondo, F., Fukusato, T., Tsuneyama, K., et al. (2010) · Pathology International · doi:10.1111/j.1440-1827.2009.02500.x · Cited by 224
Kita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z.-X., Van de Water, J., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214698 · Cited by 222
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites
Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222
Kita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z., de Water, J. V., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14698 · Cited by 222
Poupon, R. E., Lindor, K. D., Parés, A. R., Chazouillères, O., Poupon, R. Y., & Heathcote, E. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00192-2 · Cited by 216
Self-citationVariants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis
Hirschfield, G. M., Liu, X., Han, Y., Gorlov, I. P., Lu, Y., Xu, C., Lu, Y., Chen, W., Juran, B. D., Coltescu, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.631 · Cited by 215
Self-citationFamilial primary biliary cirrhosis reassessed: a geographically-based population study
Jones, D. E., Watt, F. E., Metcalf, J. V., Bassendine, M. F., & James, O. F. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80097-x · Cited by 213
A Controlled Trial of Cyclosporine in the Treatment of Primary Biliary Cirrhosis
Wiesner, R. H., Ludwig, J., Lindor, K. D., Jorgensen, R. A., Baldus, W. P., Homburger, H. A., & Dickson, E. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005173222003 · Cited by 211
Self-citationTen-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209
Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30319-7 · Cited by 206
Angulo, P., Lindor, K. D., Therneau, T. M., Jorgensen, R. A., Malinchoc, M., Kamath, P. S., & Dickson, E. R. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00020.x · Cited by 203
Self-citationHepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202
A controlled trial of prednisolone treatment in primary biliary cirrhosis
Mitchison, H. C., Palmer, J. M., Bassendine, M. F., Watson, A. J., Record, C. O., & James, O. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90065-w · Cited by 199
Chazouillères, O., Wendum, D., Serfaty, L., Rosmorduc, O., & Poupon, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.017 · Cited by 194
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Self-citationHyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
Longo, M., Crosignani, A., Battezzati, P. M., Squarcia Giussani, C., Invernizzi, P., Zuin, M., & Podda, M. (2002) · Gut · doi:10.1136/gut.51.2.265 · Cited by 190
Extrahepatic autoimmune conditions associated with primary biliary cirrhosis
Floreani, A., Franceschet, I., Cazzagon, N., Spinazzè, A., Buja, A., Furlan, P., Baldo, V., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8427-x · Cited by 188
Hypothesis The Pruritus of Cholestasis: From Bile Acids to Opiate Agonists
Jones, E. A., & Bergasa, N. V. (1990) · Hepatology · doi:10.1002/hep.1840110526 · Cited by 188
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186
Self-citationTime course of histological progression in primary biliary cirrhosis
Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D. (1996) · Hepatology · doi:10.1002/hep.510230108 · Cited by 184
Self-citationAntimitochondrial antibody-negative primary biliary cirrhosis.
Lacerda, M. A., Ludwig, J., Dickson, E. R., Jorgensen, R. A., & Lindor, K. (1995) · PubMed · Cited by 182
Self-citationOpen‐label trial of oral nalmefene therapy for the pruritus of cholestasis
Bergasa, N. V., Schmitt, J. M., Talbot, T. L., Alling, D. W., Swain, M. G., Turner, M. L., Jenkins, J. B., & Jones, A. E. (1998) · Hepatology · doi:10.1002/hep.510270307 · Cited by 182
Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis
Datta, D. V., & Sherlock, S. (1966) · Gastroenterology · doi:10.1016/s0016-5085(66)80071-9 · Cited by 181
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression
Menon, K. V. N., Angulo, P., Weston, S., Dickson, E. R., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00144-1 · Cited by 180
Self-citationWakabayashi, K., Lian, Z., Leung, P. S. C., Moritoki, Y., Tsuneyama, K., Kurth, M. J., Lam, K. S., Yoshida, K., Yang, G., Hibi∥, T., et al. (2008) · Hepatology · doi:10.1002/hep.22390 · Cited by 180
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence
Newton, J. L., Gibson, J. G., Tomlinson, M., Wilton, K., & Jones, D. E. (2006) · Hepatology · doi:10.1002/hep.21230 · Cited by 179
Charatcharoenwitthaya, P., Pimentel, S., Talwalkar, J. A., Enders, F. T., Lindor, K. D., Krom, R. A. F., & Wiesner, R. H. (2007) · Liver Transplantation · doi:10.1002/lt.21124 · Cited by 179
Self-citationAngulo, P., Jorgensen, R. A., Keach, J. C., Dickson, R. E., Smith, C., & Lindor, K. D. (2000) · Hepatology · doi:10.1002/hep.510310209 · Cited by 179
Self-citationTandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176
Degott, C., Zafrani, E. S., Callard, P., Balkau, B., Poupon, R. E., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290444 · Cited by 174
Joshi, S., Cauch-Dudek, K., Wanless, I. R., Lindor, K. D., Jorgensen, R., Batts, K., & Heathcote, J. E. (2002) · Hepatology · doi:10.1053/jhep.2002.30902 · Cited by 174
Self-citationGores, G. J., Wiesner, R. H., Dickson, E. R., Zinsmeister, A. R., Jorgensen, R. A., & Langworthy, A. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90526-x · Cited by 173
Changing Nomenclature for PBC: From ‘Cirrhosis’ to ‘Cholangitis’
Beuers, U. H., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E., Lindor, K. D., Ma, X., Mackay, I. R., Parés, A. R., Tanaka, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.031 · Cited by 173
Self-citationCase‐control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations
Prince, M. I., Ducker, S. J., & James, O. F. W. (2010) · Gut · doi:10.1136/gut.2009.184218 · Cited by 171
Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis
Poupon, R., Chazouilleres, O., Corpechot, C., & Chrétien, Y. (2006) · Hepatology · doi:10.1002/hep.21229 · Cited by 170
Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review
Sorokin, A., Brown, J. L., & Thompson, P. D. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.036 · Cited by 169
Corpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169
Trial of Penicillamine in Advanced Primary Biliary Cirrhosis
Dickson, E. R., Fleming, T. R., Wiesner, R. H., Baldus, W. P., Fleming, C. R., Ludwig, J., & McCall, J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198504183121602 · Cited by 166
Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis
Lindor, K. D., Jorgensen, R. A., Therneau, T. M., Malinchoc, M., & Dickson, E. R. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.12.1137 · Cited by 166
Self-citationOverlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes
Silveira, M. G., Talwalkar, J. A., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01136.x · Cited by 165
Self-citationMahl, T. C., Shockcor, W., & Boyer, J. L. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80139-4 · Cited by 163
Self-citationBergasa, N. V., Alling, D. W., Talbot, T. L., Wells, M. C., & Jones, E. A. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70117-9 · Cited by 163
Khurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162
Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
Jones, D. E., Metcalf, J. V., Collier, J. D., Bassendine, M. F., & James, O. F. (1997) · Hepatology · doi:10.1002/hep.510260508 · Cited by 161
Randomized trial of chlorambucil for primary biliary cirrhosis
Hoofnagle, J. H., Davis, G. L., Schafer, D. F., Peters, M., Avigan, M. I., Pappas, S. C., Hanson, R. G., Minuk, G. Y., Dusheiko, G. M., Campbell, G., et al. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90183-6 · Cited by 157
Neuberger, J., Gunson, B., Hubscher, S., & Nightingale, P. (2004) · Liver Transplantation · doi:10.1002/lt.20123 · Cited by 155
Ghent, C. N., Bloomer, J. R., & Klatskin, G. (1977) · Gastroenterology · doi:10.1016/s0016-5085(19)31870-0 · Cited by 154
Juran, B. D., Hirschfield, G. M., Invernizzi, P., Atkinson, E. J., Li, Y., Xie, G., Kosoy, R., Ransom, M., Sun, Y., Bianchi, I., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds359 · Cited by 150 · cited 1×
“(10, 11) In addition to the high concordance among monozygotic twins compared with dizygotic twins with PBC(5), the strong association with human leukocyte antigen alleles, which vary by ethnicity, supports a genetic cause of inherited risk.(12-20) Despite progress, only an estimated 15% of the variability of the dise…”
BackgroundSelf-citationSylvestre, P. B., Batts, K. P., Burgart, L. J., Poterucha, J. J., & Wiesner, R. H. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50213 · Cited by 148
Lombard, M., Portmann, B., Neuberger, J., Williams, R., Tygstrup, N., Ranek, L., Ring-Larsen, H., Rodés, J., Navasa, M., Trepo, C., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90422-9 · Cited by 148
Transplantation trends in primary biliary cirrhosis
Lee, J., Belanger, A., Doucette, J. T., Stanca, C., Friedman, S., & Bach, N. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.07.015 · Cited by 147
Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
O'Brien, C., Joshi, S., Feld, J. J., Guindi, M., Dienes, H. P., & Heathcote, E. J. (2008) · Hepatology · doi:10.1002/hep.22380 · Cited by 146
Characterization of antimitochondrial antibodies in healthy adults
Mattalia, A., Quaranta, S., Leung, P. S. C., Bauducci, M., Van de Water, J., Calvo, P. L., Danielle, F., Rizzetto, M., Ansari, A., Coppel, R. L., et al. (1998) · Hepatology · doi:10.1002/hep.510270303 · Cited by 146
Topical ciclosporin in the treatment of ocular surface disorders
Tatlıpınar, S. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.070888 · Cited by 144
Quality of life in patients with primary biliary cirrhosis
Poupon, R. E., Chrétien, Y., Chazouillères, O., Poupon, R., & Chwalow, J. (2004) · Hepatology · doi:10.1002/hep.20276 · Cited by 144
Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142
Self-citationNatural history of pruritus in primary biliary cirrhosis
Talwalkar, J. A., Souto, E., Jorgensen, R. A., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00134-4 · Cited by 141
Self-citationAsymptomatic primary biliary cirrhosis: a study of its natural history and prognosis
Springer, J., Cauch-Dudek, K., O'Rourke, K., Wanless, I. R., & Heathcote, E. J. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.00770.x · Cited by 141
Presentation and course of asymptomatic primary biliary cirrhosis
Long, R. G., Scheuer, P. J., & Sherlock, S. (1977) · Gastroenterology · doi:10.1016/s0016-5085(77)80011-5 · Cited by 140
A genome-wide association study identifies six novel risk loci for primary biliary cholangitis
Qiu, F., Tang, R., Zuo, X., Shi, X., Wei, Y., Zheng, X., Dai, Y., Gong, Y., Wang, L., Xu, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms14828 · Cited by 140
Dahlqvist, G., Gaouar, F., Carrat, F., Meurisse, S., Chazouillères, O., Poupon, R., Johanet, C., & Corpechot, C. (2017) · Hepatology · doi:10.1002/hep.28859 · Cited by 137
Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort
Jones, D. E. J., Bhala, N., Burt, J., Goldblatt, J., Prince, M., & Newton, J. L. (2006) · Gut · doi:10.1136/gut.2005.080317 · Cited by 136 · cited 1×
“(95-96) Severe fatigue may be associated with decreased overall survival.(97) The etiology of the fatigue in PBC is unknown, but in some it may be associated with orthostatic hypotension, daytime sleepiness, cognitive defects, or impaired recovery of muscle from acidosis.”
BackgroundAngulo, P., Dickson, E. R., Therneau, T. M., Jorgensen, R. A., Smith, C., DeSotel, C. K., Lange, S. M., Anderson, M. L., Mahoney, D. W., & Lindor, K. D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80136-6 · Cited by 134
Self-citationMoteki, S., Leung, P. S., Dickson, E. R., Van Thiel, D. H., Galperin, C., Buch, T., Alarcon-Segovia, D., Kershenobich, D., Kawano, K., Coppel, R. L., et al. (1996) · Hepatology · doi:10.1002/hep.510230307 · Cited by 133
Kuiper, E. M. M., van Erpecum, K. J., Beuers, U., Hansen, B. E., Thio, B. H., de Man, R. A., Janssen, H. L. A., & van Buuren, H. R. (2010) · Hepatology · doi:10.1002/hep.23821 · Cited by 132
Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.029 · Cited by 132
Gong, Y., Huang, Z., Christensen, E., & Gluud, C. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01235.x · Cited by 131
Lazaridis, K. N., Juran, B. D., Boe, G. M., Slusser, J. P., de Andrade, M., Homburger, H. A., Ghosh, K., Dickson, R. E., Lindor, K. D., & Petersen, G. M. (2007) · Hepatology · doi:10.1002/hep.21749 · Cited by 128
Self-citationTalwalkar, J. A., Keach, J. C., Angulo, P., & Lindor, K. D. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05703.x · Cited by 127
Self-citationBone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?
Lindor, K. D., Janes, C. H., Crippin, J. S., Jorgensen, R. A., & Dickson, R. E. (1995) · Hepatology · doi:10.1002/hep.1840210219 · Cited by 126
Self-citationPhenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Self-citationGuañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., et al. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07639.x · Cited by 119
Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis
Neuhauser, M., Bjornsson, E., Treeprasertsuk, S., Enders, F., Silveira, M., Talwalkar, J., & Lindor, K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.616 · Cited by 116
Self-citationCarbone, M., Bufton, S., Monaco, A., Griffiths, L., Jones, D. E., & Neuberger, J. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.017 · Cited by 115 · cited 2×
“Fatigue improves in a subset of patients with PBC, but moderate to severe fatigue continues to affect nearly half of patients 2 years after liver transplantation.(189)”
BackgroundReig, A., Sesé, P., & Parés, A. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.287 · Cited by 115
Taylor, S. L., Dean, P. J., & Riely, C. A. (1994) · PubMed · Cited by 114
Bosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.-Y., Wendum, D., Conti, F., Morard, I., Rubbia-Brandt, L., Terris, B., Radenne, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.038 · Cited by 114
JONES, D. E. J., & NEWTON, J. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03223.x · Cited by 114
Pares, A., Cisneros, L., Salmeron, J. M., Caballeria, L., Mas, A., Torras, A., & Rodes, J. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30204.x · Cited by 112
Duclos‐Vallée, J., & Sebagh, M. (2009) · Liver Transplantation · doi:10.1002/lt.21916 · Cited by 112
Vuoristo, M., Färkkilä, M. A., Karvonen, A., Leino, R., Lehtola, J., Mäkinen, J., Mattila, J. J., Friman, C., Seppälä, K., Tuominen, J., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90696-7 · Cited by 111
The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine
Van Itallie, T. B., Hashim, S. A., Crampton, R. S., & Tennent, D. M. (1961) · New England Journal of Medicine · doi:10.1056/nejm196109072651004 · Cited by 110
Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.
Neuberger, J., Christensen, E., Portmann, B. C., Caballería, J., Rodés, J., Ranek, L., Tygstrup, N., & Williams, R. L. (1985) · Gut · doi:10.1136/gut.26.2.114 · Cited by 109
Grambsch, P. M., Dickson, R. E., Kaplan, M., Lesage, G., Fleming, T. R., & Langworthy, A. L. (1989) · Hepatology · doi:10.1002/hep.1840100516 · Cited by 107
Itch in primary biliary cirrhosis: a patients' perspective
Rishe, E., Azarm, A., & Bergasa, N. (2008) · Acta Dermato-Venereologica · doi:10.2340/00015555-0350 · Cited by 107
Ondansetron for pruritus due to cholestasis
Raderer, M., Muller, C., & Scheithauer, W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405263302117 · Cited by 104
Colombato, L. A., Alvarez, F., Côté, J., & Huet, P.-M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90829-x · Cited by 104
Hendrickse, M. T., Rigney, E., Giaffer, M. H., Soomro, I. N., Triger, D. R., Underwood, J. C. E., & Gleeson, D. C. (1999) · Gastroenterology · doi:10.1053/gast.1999.0029900400 · Cited by 101
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?
Zein, C. O., Angulo, P., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1053/cgh.2003.50014 · Cited by 99
Self-citationGuañabens, N., Monegal, A., Cerdá, D., Muxí, Á., Gifre, L., Peris, P., & Parés, A. (2013) · Hepatology · doi:10.1002/hep.26466 · Cited by 99
Incidence of cancer in primary biliary cirrhosis: the Mayo experience
Nijhawan, P. K., Therneau, T. M., Dickson, R. E., Boynton, J., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290511 · Cited by 99
Self-citationTaylor, S. L., Dean, P. J., & Riely, C. A. (1994) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199401000-00009 · Cited by 95
Induction of Primary Biliary Cirrhosis in Guinea Pigs following Chemical Xenobiotic Immunization
Leung, P. S. C., Park, O., Tsuneyama, K., Kurth, M. J., Lam, K. S., Ansari, A. A., Coppel, R. L., & Gershwin, M. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2651 · Cited by 94
Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers
Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00006-5 · Cited by 94
Allocca, M., Crosignani, A., Gritti, A., Ghilardi, G., Gobatti, D., Caruso, D., Zuin, M., Podda, M., & Battezzati, P. M. (2006) · Gut · doi:10.1136/gut.2005.079814 · Cited by 92
Angulo, P., Patel, T. C., Jorgensen, R. A., Therneau, T. M., & Lindor, K. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18663 · Cited by 90
Self-citationClinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis
Poupon, R., Chazouillères, O., Balkau, B., & Poupon, R. E. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80098-1 · Cited by 90
Natural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89
Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis
Czaja, A. J., Muratori, P., Muratori, L., Carpenter, H. A., & Bianchi, F. B. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0924.x · Cited by 89
Samur, S., Klebanoff, M., Banken, R., Pratt, D. S., Chapman, R., Ollendorf, D. A., Loos, A. M., Corey, K., Hur, C., & Chhatwal, J. (2017) · Hepatology · doi:10.1002/hep.28932 · Cited by 89
Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis
Norman, G. L., Yang, C., Ostendorff, H. P., Shums, Z., Lim, M. J., Wang, J., Awad, A., Hirschfield, G. M., Milkiewicz, P., Bloch, D. B., et al. (2015) · Liver International · doi:10.1111/liv.12690 · Cited by 87
Self-citationKaplan, M. M., Cheng, S., Price, L. L., & Bonis, P. A. L. (2004) · Hepatology · doi:10.1002/hep.20103 · Cited by 87
Nyberg, A., & Lööf, L. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909092240 · Cited by 86
Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis
van Os, E., van den Broek, W. W., Mulder, P. G. H., ter Borg, P. C. J., Bruijn, J. A., & van Buuren, H. R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.036 · Cited by 86
Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease.
Carson, K. L., Tran, T. T., Cotton, P. B., Sharara, A. I., & Hunt, C. M. (1996) · PubMed · Cited by 83
Lü, M., Li, J., Haller, I. V., Romanelli, R. J., VanWormer, J. J., Rodriguez, C. V., Raebel, M. A., Boscarino, J. A., Schmidt, M. A., Daida, Y. G., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.10.018 · Cited by 82
Self-citationHeurgué, A., Vitry, F., Diebold, M.-D., Yaziji, N., Bernard-Chabert, B., Pennaforte, J.-L., Picot, R., Louvet, H., Frémond, L., Geoffroy, P., et al. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89323-7 · Cited by 80
Bizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
Improvement of cholestatic pruritus by ondansetron
Schwörer, H., & Ramadori, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91178-o · Cited by 79
Bressler, B. L. (2005) · Gut · doi:10.1136/gut.2004.040832 · Cited by 78
Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.
Jorgensen, R. A., Dickson, E. R., Hofmann, A. F., Rossi, S. S., & Lindor, K. D. (1995) · Gut · doi:10.1136/gut.36.6.935 · Cited by 77
Self-citationLevy, C., Naik, J., Giordano, C., Mandalia, A., O'Brien, C., Bhamidimarri, K. R., Schiff, E. R., & Martin, P. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.12.010 · Cited by 77
Self-citationOptimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Momah, N., Silveira, M. G., Jorgensen, R., Sinakos, E., & Lindor, K. D. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02678.x · Cited by 77
Self-citationHoensch, H. P., Balzer, K., Dylewizc, P., Kirch, W., Goebell, H., & Ohnhaus, E. E. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544371 · Cited by 76
Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial
Lindor, K. D., Jorgensen, R. A., Tiegs, R. D., Khosla, S., & Dickson, E. R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80118-x · Cited by 75
Self-citationPortal hypertension in primary biliary cirrhosis.
Kew, M. C., Varma, R. R., Santos, H. D., & Scheuer, P. J. (1971) · PubMed · Cited by 75
Symptom development and prognosis in primary biliary cirrhosis: a study in two centers
Mitchison, H. C., Lucey, M. R., Kelly, P. J., Neuberger, J. M., Williams, R., & James, O. F. W. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90968-7 · Cited by 74
Pain as a complication of use of opiate antagonists for symptom control in cholestasis
Mcrae, C. A., Prince, M. I., Hudson, M., Day, C. P., James, O. F. W., & Jones, D. E. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00879-5 · Cited by 73
Theal, J. J., Toosi, M. N., Girlan, L., Heslegrave, R. J., Huet, P., Burak, K. W., Swain, M., Tomlinson, G. A., & Heathcote, E. J. (2005) · Hepatology · doi:10.1002/hep.20698 · Cited by 73
Portal hypertension in primary biliary cirrhosis
Kew, M. C., Varma, R. R., Santos, H. A. D., & Scheuer, P. J. (1971) · Gut · doi:10.1136/gut.12.10.830 · Cited by 73
Abraham, S. C., Kamath, P. S., Eghtesad, B., Demetris, A. J., & Krasinskas, A. M. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213286.65907.ea · Cited by 72
Combes, B., Carithers, R. L., Maddrey, W. C., Lin, D. P., McDonald, M. F., Wheeler, D. E., Eigenbrodt, E. H., oz, S. J. M., Rubin, R., Garcia-Tsao, G., et al. (1995) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199511000-00024 · Cited by 72
Self-citationYang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., Chen, X., Bian, Z., Zhang, H., Yang, Y., et al. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8516-5 · Cited by 71
Selmi, C. F., Cavaciocchi, F., Lleò, A., Cheroni, C., Francesco, R. D., Lombardi, S. A., Santis, M. D., Meda, F., Raimondo, M. G., Crotti, C., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00128 · Cited by 71
Self-citationSurveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis
Silveira, M. G., Suzuki, A., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22458 · Cited by 68
Self-citationPrevalence of Primary Biliary Cirrhosis–Autoimmune Hepatitis Overlap Syndrome
Bonder, A., Retana, A., Winston, D. M., Leung, J., & Kaplan, M. M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.019 · Cited by 67
Conventional Therapy of Sjogren’s Syndrome
Mavragani, C. P., & Moutsopoulos, H. Μ. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8008-3 · Cited by 67
Relief from profound fatigue associated with chronic liver disease by long‐term ondansetron therapy
Jones, E. A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02936-0 · Cited by 66
Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management
Jopson, L., & Jones, D. E. J. (2015) · Digestive Diseases · doi:10.1159/000440757 · Cited by 66
Research works printed but not linked: 2
- 2016, Screening of antimitochondrial antibody subtype M2 in residents at least 18 years of age in an urban district of Shanghai, China. Eur Rev Med Pharmacol Sci, 20, 2052
- 2005, Practice Guidelines Committee AAftSoLD, Management of hepatocellular carcinoma. Hepatology, 42, 1208
Cited by
Sorted by citations
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01788-x · Cited by 462
“European and American guidelines recommend a dose of 13 to 15 mg/kg of body weight per day [52, 53].”
BackgroundDiagnosis and Management of Cirrhosis and Its Complications
Tapper, E. B., & Parikh, N. D. (2023) · JAMA · doi:10.1001/jama.2023.5997 · Cited by 422
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.001 · Cited by 289
Self-citationA Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286
Self-citation
Metadata
- Authors
- Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M.
- Affiliations
- Mayo Clinic (US)
- University of California, Davis (US)
- Yale University (US)
- University of Miami (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Lindor, Keith D.
- Venue
- Hepatology
- Published
- 2018-11-06
- Volume
- 69
- Issue
- 1
- Pages
- 394-419
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2886703787
- Cited by
- 913
- References
- 263
- Citations by year
- 2026: 126 · 2025: 147 · 2024: 143 · 2023: 131 · 2022: 114 · 2021: 113 · 2020: 81 · 2019: 55 · 2018: 2
- FWCI
- 39.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Allergan
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, obeticholic acid, antimitochondrial antibodies, autoimmune etiology, diagnosis, imaging, clinical features, treatment, screening, cholestasis, liver fibrosis, biliary strictures, cholangitis
- MeSH terms
- Humans, Liver Cirrhosis, Biliary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
